Kurozumi, Sasagu http://orcid.org/0000-0002-9971-2918
Inoue, Kenichi
Matsumoto, Hiroshi
Fujii, Takaaki
Horiguchi, Jun
Oyama, Tetsunari
Kurosumi, Masafumi
Shirabe, Ken
Article History
Received: 1 February 2019
Accepted: 24 October 2019
First Online: 13 November 2019
Competing interests
: K.I. received remuneration from CHUGAI Pharmaceutical Co., Ltd. K.I. received research funding from PAREXEL International Corp., Puma Biotechnology, Inc., Merck Sharp & Dohme Ltd., Novartis Pharma K.K., GlaxoSmithKline K.K., Pfizer Inc., CHUGAI Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., and Daiichi Sankyo Co., Ltd. MK received honoraria from Taiho Pharmaceutical Co., Ltd. and CHUGAI Pharmaceutical Co., Ltd. F.T. received research funding from Eisai Co., Ltd. There were no conflicts of interest for any of the other authors.